<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_empagliflozin" title="The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes" shortTitle="empagliflozin" author="Francesca Iannantuoni, Aranzazu M. de Marañon, Noelia Diaz-Morales, Rosa Falcon, Celia Bañuls, Zaida Abad-Jimenez, Victor  M. Victor, Antonio Hernandez-Mijares, Susana Rovira-Llopis" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2077-0383/8/11/1814/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
4.	LS	4.
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
iSGLT2s	NNS	isglt
are	VBP	be
a	DT	a
new	JJ	new
class	NN	class
of	IN	of
oral	JJ	oral
hypoglycaemic	JJ	hypoglycaemic
drugs	NNS	drug
that	WDT	that
block	VBP	block
glucose	NN	glucose
reabsorption	NN	reabsorption
at	IN	at
the	DT	the
renal	JJ	renal
level	NN	level
,	,	,
thus	RB	thus
promoting	VBG	promote
urine	NN	urine
glucose	NN	glucose
and	CC	and
sodium	NN	sodium
excretion	NN	excretion
and	CC	and
reducing	VBG	reduce
plasma	NN	plasma
glucose	NN	glucose
levels	NNS	level
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
present	JJ	present
study	NN	study
,	,	,
we	PRP	we
have	VBP	have
focused	VBN	focus
on	IN	on
the	DT	the
effects	NNS	effect
of	IN	of
empagliflozin	NN	empagliflozin
on	IN	on
oxidative	JJ	oxidative
stress	NN	stress
in	IN	in
the	DT	the
leukocytes	NNS	leukocyte
of	IN	of
T2D	NNP	T2D
subjects	NNS	subject
,	,	,
and	CC	and
on	IN	on
inflammatory	JJ	inflammatory
parameters	NNS	parameter
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
to	IN	to
a	DT	a
reduction	NN	reduction
in	IN	in
body	NN	body
weight	NN	weight
and	CC	and
an	DT	a
improved	VBN	improve
metabolic	JJ	metabolic
profile	NN	profile
—	:	—
characterized	VBN	characterize
by	IN	by
reduced	VBN	reduce
plasma	NN	plasma
glucose	NN	glucose
and	CC	and
HbA1c	NN	HbA1c
levels	NNS	level
—	:	—
we	PRP	we
observed	VBD	observe
a	DT	a
reduction	NN	reduction
in	IN	in
mitochondrial	JJ	mitochondrial
superoxide	NN	superoxide
production	NN	production
in	IN	in
diabetic	JJ	diabetic
patients	NNS	patient
after	IN	after
treatment	NN	treatment
with	IN	with
the	DT	the
iSGLT2	NNP	iSGLT2
empagliflozin	NN	empagliflozin
,	,	,
together	RB	together
with	IN	with
increased	VBN	increase
antioxidant	JJ	antioxidant
defenses	NNS	defense
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
reduced	VBN	reduce
proinflammatory	JJ	proinflammatory
markers	NNS	marker
and	CC	and
increased	VBD	increase
anti-inflammatory	JJ	anti-inflammatory
parameters	NNS	parameter
were	VBD	be
maintained	VBN	maintain
after	IN	after
24	CD	24
weeks	NNS	week
of	IN	of
treatment	NN	treatment
with	IN	with
empagliflozin	NN	empagliflozin
.	.	.
</s>
<s type="decl">
Besides	IN	besides
their	PRP$	their
glucose-lowering	NN	glucose-lowering
effect	NN	effect
,	,	,
iSGLT2s	NNS	isglt
produce	VBP	produce
changes	NNS	change
in	IN	in
the	DT	the
lipid	NN	lipid
profile	NN	profile
that	WDT	that
should	MD	should
also	RB	also
be	VB	be
highlighted	VBN	highlight
.	.	.
</s>
<s type="decl">
Empagliflozin	NNP	Empagliflozin
treatment	NN	treatment
is	VBZ	be
correlated	VBN	correlate
with	IN	with
increased	VBN	increase
total	JJ	total
cholesterol	NN	cholesterol
due	JJ	due
to	IN	to
slight	JJ	slight
increases	NNS	increase
in	IN	in
HDL-c	NNP	HDL-c
and	CC	and
LDL-c	NNP	LDL-c
,	,	,
as	IN	as
we	PRP	we
have	VBP	have
observed	VBN	observe
,	,	,
and	CC	and
reported	VBN	report
in	IN	in
other	JJ	other
studies	NNS	study
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
there	EX	there
is	VBZ	be
a	DT	a
well-documented	JJ	well-documented
cardiovascular	JJ	cardiovascular
protection	NN	protection
exerted	VBN	exert
by	IN	by
iSGLT2s	NNPS	iSGLTl
,	,	,
which	WDT	which
endows	VBZ	endow
these	DT	this
drugs	NNS	drug
with	IN	with
clinical	JJ	clinical
potential	NN	potential
.	.	.
</s>
<s type="decl">
This	DT	this
has	VBZ	have
been	VBN	be
reflected	VBN	reflect
by	IN	by
several	JJ	several
studies	NNS	study
,	,	,
such	JJ	such
as	IN	as
the	DT	the
EMPA-REG	NNP	Empa-reg
OUTCOME	NNP	OUTCOME
study	NN	study
in	IN	in
which	WDT	which
a	DT	a
reduction	NN	reduction
of	IN	of
38	CD	38
%	NN	%
in	IN	in
cardiovascular	JJ	cardiovascular
mortality	NN	mortality
was	VBD	be
evident	JJ	evident
in	IN	in
the	DT	the
empagliflozin	NN	empagliflozin
vs.	IN	versus
placebo	NN	placebo
group	NN	group
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
neither	CC	neither
the	DT	the
reduction	NN	reduction
in	IN	in
HbA1c	NNP	HbA1c
observed	VBD	observe
in	IN	in
the	DT	the
study	NN	study
(	-LRB-	(
0.60	CD	0.60
%	NN	%
over	IN	over
12	CD	12
weeks	NNS	week
)	-RRB-	)
nor	CC	nor
the	DT	the
reduction	NN	reduction
in	IN	in
SBP	NNP	SBP
(	-LRB-	(
up	RB	up
to	IN	to
5	CD	5
mmHg	NN	mmHg
)	-RRB-	)
are	VBP	be
sufficient	JJ	sufficient
to	TO	to
explain	VB	explain
the	DT	the
reported	VBN	report
protection	NN	protection
against	IN	against
cardiovascular	JJ	cardiovascular
mortality	NN	mortality
.	.	.
</s>
</p>
<p>
<s type="decl">
Interestingly	RB	interestingly
,	,	,
as	RB	as
little	RB	little
as	IN	as
24	CD	24
weeks	NNS	week
of	IN	of
treatment	NN	treatment
with	IN	with
iSGLT2	NNP	iSGLT2
is	VBZ	be
sufficient	JJ	sufficient
to	TO	to
witness	VB	witness
their	PRP$	their
beneficial	JJ	beneficial
effects	NNS	effect
on	IN	on
HbA1c	NN	HbA1c
,	,	,
body	NN	body
weight	NN	weight
,	,	,
blood	NN	blood
pressure	NN	pressure
and	CC	and
,	,	,
most	RBS	most
importantly	RB	importantly
,	,	,
on	IN	on
the	DT	the
cardiovascular	JJ	cardiovascular
system	NN	system
.	.	.
</s>
<s type="decl">
As	IN	as
an	DT	a
example	NN	example
,	,	,
the	DT	the
reduction	NN	reduction
in	IN	in
hospitalization	NN	hospitalization
rates	NNS	rate
for	IN	for
heart	NN	heart
failure	NN	failure
in	IN	in
the	DT	the
group	NN	group
treated	VBN	treat
with	IN	with
empagliflozin	NN	empagliflozin
in	IN	in
the	DT	the
EMPA-REG	NNP	Empa-reg
OUTCOME	NNP	OUTCOME
study	NN	study
was	VBD	be
already	RB	already
significant	JJ	significant
at	IN	at
this	DT	this
time	NN	time
point	NN	point
.	.	.
</s>
<s type="decl">
A	DT	a
recent	JJ	recent
study	NN	study
demonstrated	VBD	demonstrate
an	DT	a
improved	VBN	improve
arterial	JJ	arterial
stiffness	NN	stiffness
after	IN	after
6	CD	6
weeks	NNS	week
of	IN	of
treatment	NN	treatment
with	IN	with
empagliflozin	NN	empagliflozin
in	IN	in
T2D	NN	T2D
patients	NNS	patient
,	,	,
and	CC	and
hs-CRP	NNP	hs-CRP
was	VBD	be
shown	VBN	show
to	TO	to
be	VB	be
one	CD	one
of	IN	of
the	DT	the
main	JJ	main
significant	JJ	significant
determinants	NNS	determinant
for	IN	for
this	DT	this
improvement	NN	improvement
.	.	.
</s>
<s type="decl">
Nevertheless	RB	nevertheless
,	,	,
despite	IN	despite
the	DT	the
available	JJ	available
evidence	NN	evidence
,	,	,
the	DT	the
molecular	JJ	molecular
mechanisms	NNS	mechanism
underlying	VBG	underlie
the	DT	the
cardiovascular	JJ	cardiovascular
protection	NN	protection
attributable	JJ	attributable
to	IN	to
iSGLT2	NNP	iSGLT2
treatment	NN	treatment
are	VBP	be
still	RB	still
unknown	JJ	unknown
,	,	,
though	IN	though
amelioration	NN	amelioration
of	IN	of
oxidative	NN	oxidative
stress	NN	stress
has	VBZ	have
been	VBN	be
hypothesized	VBN	hypothesize
to	TO	to
be	VB	be
a	DT	a
potential	JJ	potential
contributor	NN	contributor
.	.	.
</s>
<s type="decl">
Because	IN	because
cardiac	JJ	cardiac
tissue	NN	tissue
possesses	VBZ	possess
low	JJ	low
antioxidant	NN	antioxidant
defenses	NNS	defense
,	,	,
increasing	VBG	increase
the	DT	the
expression	NN	expression
or	CC	or
activity	NN	activity
of	IN	of
antioxidant	JJ	antioxidant
enzymes	NNS	enzyme
could	MD	could
be	VB	be
a	DT	a
mechanism	NN	mechanism
of	IN	of
cardiac	JJ	cardiac
protection	NN	protection
under	IN	under
high	JJ	high
risk	NN	risk
situations	NNS	situation
such	JJ	such
as	IN	as
T2D	NN	T2D
.	.	.
</s>
</p>
<p>
<s type="decl">
Oxidative	NN	oxidative
stress	NN	stress
occurs	VBZ	occur
when	WRB	when
the	DT	the
production	NN	production
of	IN	of
pro-oxidant	JJ	pro-oxidant
species	NNS	species
overcomes	VBZ	overcome
the	DT	the
intrinsic	JJ	intrinsic
antioxidant	JJ	antioxidant
defense	NN	defense
system	NN	system
of	IN	of
the	DT	the
cell	NN	cell
,	,	,
thus	RB	thus
triggering	VBG	trigger
damage	NN	damage
to	IN	to
lipids	NNS	lipid
,	,	,
proteins	NNS	protein
and	CC	and
DNA	NN	DNA
,	,	,
and	CC	and
eventually	RB	eventually
compromising	VBG	compromise
cellular	JJ	cellular
and	CC	and
tissue	NN	tissue
function	NN	function
.	.	.
</s>
<s type="decl">
Exploring	VBG	explore
the	DT	the
role	NN	role
of	IN	of
SGLT2	NN	SGLT2
inhibition	NN	inhibition
in	IN	in
the	DT	the
prevention	NN	prevention
or	CC	or
reduction	NN	reduction
of	IN	of
oxidative	JJ	oxidative
stress	NN	stress
conditions	NNS	condition
has	VBZ	have
been	VBN	be
the	DT	the
subject	NN	subject
of	IN	of
several	JJ	several
studies	NNS	study
over	IN	over
the	DT	the
last	JJ	last
decade	NN	decade
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
to	IN	to
date	NN	date
,	,	,
most	JJS	most
of	IN	of
the	DT	the
studies	NNS	study
evaluating	VBG	evaluate
the	DT	the
effect	NN	effect
of	IN	of
iSGLT2	NNP	iSGLT2
on	IN	on
oxidative	NN	oxidative
stress	NN	stress
have	VBP	have
been	VBN	be
performed	VBN	perform
in	IN	in
animal	NN	animal
models	NNS	model
.	.	.
</s>
</p>
<p>
<s type="decl">
Our	PRP$	our
data	NNS	datum
demonstrate	VBP	demonstrate
that	IN	that
T2D	NNP	T2D
patients	NNS	patient
receiving	VBG	receive
iSGLT2	NNP	iSGLT2
treatment	NN	treatment
undergo	VBP	undergo
a	DT	a
reduction	NN	reduction
in	IN	in
mitochondrial	JJ	mitochondrial
superoxide	NN	superoxide
production	NN	production
in	IN	in
parallel	NN	parallel
to	IN	to
an	DT	a
increase	NN	increase
in	IN	in
glutathione	NN	glutathione
content	NN	content
,	,	,
and	CC	and
markedly	RB	markedly
so	RB	so
after	IN	after
24	CD	24
weeks	NNS	week
of	IN	of
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
This	DT	this
is	VBZ	be
accompanied	VBN	accompany
by	IN	by
increased	VBN	increase
expression	NN	expression
of	IN	of
the	DT	the
antioxidant	NN	antioxidant
enzymes	NNS	enzyme
GSR	NNP	GSR
and	CC	and
CAT	NNP	CAT
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
no	DT	no
changes	NNS	change
in	IN	in
plasma	NN	plasma
protein	NN	protein
carbonyl	NN	carbonyl
content	NN	content
were	VBD	be
observed	VBN	observe
with	IN	with
empagliflozin	NN	empagliflozin
treatment	NN	treatment
at	IN	at
these	DT	this
time-points	NNS	time-point
.	.	.
</s>
<s type="decl">
Whether	IN	whether
this	DT	this
could	MD	could
be	VB	be
due	JJ	due
to	IN	to
the	DT	the
small	JJ	small
sample	NN	sample
size	NN	size
or	CC	or
would	MD	would
require	VB	require
long-term	JJ	long-term
empagliflozin	NN	empagliflozin
treatment	NN	treatment
needs	VBZ	need
to	TO	to
be	VB	be
addressed	VBN	address
in	IN	in
future	JJ	future
research	NN	research
.	.	.
</s>
<s type="decl">
Our	PRP$	our
findings	NNS	finding
are	VBP	be
in	IN	in
accordance	NN	accordance
with	IN	with
previous	JJ	previous
studies	NNS	study
in	IN	in
rat	NN	rat
models	NNS	model
of	IN	of
T2D	NN	T2D
,	,	,
in	IN	in
which	WDT	which
increased	VBN	increase
antioxidant	JJ	antioxidant
enzyme	NN	enzyme
content	NN	content
and	CC	and
activity	NN	activity
in	IN	in
renal	JJ	renal
tissues	NNS	tissue
has	VBZ	have
been	VBN	be
reported	VBN	report
.	.	.
</s>
<s type="decl">
Furthermore	RB	furthermore
,	,	,
iSGLT2	NNP	iSGLT2
treatment	NN	treatment
in	IN	in
diabetic	JJ	diabetic
mice	NNS	mouse
has	VBZ	have
been	VBN	be
shown	VBN	show
to	TO	to
induce	VB	induce
antioxidant	NN	antioxidant
gene	NN	gene
expression	NN	expression
(	-LRB-	(
manganese-dependent	JJ	manganese-dependent
superoxide	NN	superoxide
dismutase	NN	dismutase
and	CC	and
CAT	NN	CAT
)	-RRB-	)
in	IN	in
adipose	NN	adipose
tissue	NN	tissue
and	CC	and
muscle	NN	muscle
.	.	.
</s>
</p>
</text>